What is MGF 2MG

MGF 2MG is a splice variant of the Insulin-like Growth Factor-1 (IGF-1) gene, known as Mechano Growth Factor, studied in research for its role in localized muscle repair and stem cell activation. It is intended exclusively for research use.

Regarding its chemical identity, MGF has a molecular formula of C121H200N42O39 and a molecular weight of 2888.2 g/mol. Its reported canonical sequence is Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-His-Lys. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include MGF.

Product for research use.

Mechanism of action of MGF

MGF is expressed locally in muscle tissue following mechanical stress or damage. It activates muscle satellite (stem) cells, prompting them to divide and fuse with damaged muscle fibers. This process is essential for muscle hypertrophy and the repair of tears.

Pharmacokinetics and pharmacodynamics of MGF

Native MGF has an extremely short half-life (minutes) because it is not designed to circulate; it acts purely locally in the damaged tissue. In research, it must be injected directly into the target muscle immediately following mechanical stress to be effective.

Scientific evidence on MGF

The available evidence on MGF is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Studied in models of muscle wasting, severe trauma, and muscular dystrophy. Evidence confirms that the presence of MGF is the crucial first step in the muscle repair cascade, prior to the systemic action of IGF-1.

MGF applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

MGF protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for MGF, so no trial schemes or quantities are specified.

The presentations of this product (2MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of MGF

As a general guideline for laboratory handling, lyophilized peptides such as MGF are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 2MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

MGF Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented MGF security profile

The documented safety information in open sources for MGF is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Because native MGF acts locally and degrades rapidly, systemic side effects are theoretically minimal. However, improper administration can lead to localized inflammation, and its mitogenic nature theoretically requires caution regarding uncontrolled cell growth.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

MGF in a comparative context

Unlike IGF-1 LR3, which is a systemic, long-acting growth factor, native MGF acts strictly locally and only initiates the repair process by waking up stem cells. It is often compared to PEG-MGF, which is chemically modified to survive in the bloodstream for systemic delivery.

History and development of MGF

Discovered by Dr. Geoffrey Goldspink, who identified that the IGF-1 gene splices differently in response to mechanical stress versus growth hormone stimulation, leading to the characterization of MGF as the “repair” splice variant.